[go: up one dir, main page]

MXPA06012838A - Vacuna de malaria pulmonar. - Google Patents

Vacuna de malaria pulmonar.

Info

Publication number
MXPA06012838A
MXPA06012838A MXPA06012838A MXPA06012838A MXPA06012838A MX PA06012838 A MXPA06012838 A MX PA06012838A MX PA06012838 A MXPA06012838 A MX PA06012838A MX PA06012838 A MXPA06012838 A MX PA06012838A MX PA06012838 A MXPA06012838 A MX PA06012838A
Authority
MX
Mexico
Prior art keywords
antigens
pulmonary
ama
msp
immune response
Prior art date
Application number
MXPA06012838A
Other languages
English (en)
Inventor
David A Edwards
Sandeep Kulkarni
Jean Sung
Brian Pulliam
Eric Wehrenberg-Klee
Evan Schwartz
Philip Dreyfuss
Erez Lieberman
Original Assignee
Harvard College
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Harvard College filed Critical Harvard College
Publication of MXPA06012838A publication Critical patent/MXPA06012838A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/002—Protozoa antigens
    • A61K39/015—Hemosporidia antigens, e.g. Plasmodium antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/544—Mucosal route to the airways
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invencion se refiere a composiciones particuladas para suministro, preferiblemente pulmonar, las cuales proporciona liberacion sostenida de antigenos tales como antigenos de malaria, preferiblemente, se han desarrollado antigenos de ADN y/o peptido y/o de proteinas. En la modalidad preferida, las nanoparticulas de agregados estan en el intervalo aerodinamico de 1-5 micrometros de diametro y vuelan dentro de los pulmones. Como las particulas agregadas se degradan en el cuerpo, las proteinas MSP-1 y AMA-1 son liberadas en la sangre estimulando una respuesta inmune humoral. Las particulas individuales en el intervalo de 0.1 micrones, son preferencialmente fagocitosadas por APC, las cuales expresan las proteinas codificadas por ADN plasmido de AMA-1 y MSP-1, iniciando con ello, la respuesta inmune celular que es necesaria para una inmunidad completa.
MXPA06012838A 2004-05-07 2005-05-09 Vacuna de malaria pulmonar. MXPA06012838A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US56921104P 2004-05-07 2004-05-07
PCT/US2005/016082 WO2005110379A2 (en) 2004-05-07 2005-05-09 Pulmonary malarial vaccine

Publications (1)

Publication Number Publication Date
MXPA06012838A true MXPA06012838A (es) 2007-05-15

Family

ID=34980151

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA06012838A MXPA06012838A (es) 2004-05-07 2005-05-09 Vacuna de malaria pulmonar.

Country Status (10)

Country Link
US (1) US20050265928A1 (es)
EP (1) EP1742619A2 (es)
JP (1) JP2007536273A (es)
CN (1) CN1997355A (es)
AU (1) AU2005244128B2 (es)
BR (1) BRPI0510735A (es)
CA (1) CA2565859A1 (es)
MX (1) MXPA06012838A (es)
WO (1) WO2005110379A2 (es)
ZA (1) ZA200609239B (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9150619B2 (en) 2006-09-01 2015-10-06 Csl Limited Method of elicting or inducing an immune response
SG185294A1 (en) 2007-10-12 2012-11-29 Csl Ltd Method of eliciting an immune response against pandemic influenza virus
GB0908129D0 (en) * 2009-05-12 2009-06-24 Innovata Ltd Composition

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4069819A (en) * 1973-04-13 1978-01-24 Societa Farmaceutici S.P.A. Inhalation device
US4480041A (en) * 1982-07-09 1984-10-30 Collaborative Research, Inc. Use of phosphotriester intermediates for preparation of functionalized liposomes
IT1228459B (it) * 1989-02-23 1991-06-19 Phidea S R L Inalatore con svuotamento regolare e completo della capsula.
FR2697022B1 (fr) * 1992-10-19 1994-12-16 Pasteur Institut Antigènes de Plasmodium falciparum capables d'induire des anticorps protecteurs à large spectre - Application à la vaccination.
US5698721A (en) * 1992-12-17 1997-12-16 Megabios Corporation Catonic amphiphiles
GB9301629D0 (en) * 1993-01-27 1993-03-17 Scotia Holdings Plc Formulations containing unsaturated fatty acids
WO1995024183A1 (en) * 1994-03-07 1995-09-14 Inhale Therapeutic Systems Methods and compositions for pulmonary delivery of insulin
US5814617A (en) * 1994-10-07 1998-09-29 The United States Of America As Represented By The Secretary Of The Navy Protective 17 KDA malaria hepatic and erythrocytic stage immunogen and gene
US20020052310A1 (en) * 1997-09-15 2002-05-02 Massachusetts Institute Of Technology The Penn State Research Foundation Particles for inhalation having sustained release properties
US6254854B1 (en) * 1996-05-24 2001-07-03 The Penn Research Foundation Porous particles for deep lung delivery
US5874064A (en) * 1996-05-24 1999-02-23 Massachusetts Institute Of Technology Aerodynamically light particles for pulmonary drug delivery
US5985309A (en) * 1996-05-24 1999-11-16 Massachusetts Institute Of Technology Preparation of particles for inhalation
US6042820A (en) * 1996-12-20 2000-03-28 Connaught Laboratories Limited Biodegradable copolymer containing α-hydroxy acid and α-amino acid units
CA2277801C (en) * 1997-01-16 2002-10-15 Massachusetts Institute Of Technology Preparation of particles for inhalation
US7521068B2 (en) * 1998-11-12 2009-04-21 Elan Pharma International Ltd. Dry powder aerosols of nanoparticulate drugs
GB0009773D0 (en) * 2000-04-19 2000-06-07 Univ Cardiff Particulate composition
WO2002100325A2 (en) * 2000-10-13 2002-12-19 Ligocyte Pharmaceuticals, Inc. Polyvalent nanoparticles
AU2002230609A1 (en) * 2000-12-01 2002-06-11 University Of Florida Aerodynamically light vaccine for active pulmonary immunization
GB0300885D0 (en) * 2003-01-15 2003-02-12 Secr Defence Pharmaceutical composition

Also Published As

Publication number Publication date
CN1997355A (zh) 2007-07-11
ZA200609239B (en) 2008-02-27
EP1742619A2 (en) 2007-01-17
JP2007536273A (ja) 2007-12-13
US20050265928A1 (en) 2005-12-01
CA2565859A1 (en) 2005-11-24
WO2005110379A2 (en) 2005-11-24
WO2005110379A3 (en) 2006-08-10
BRPI0510735A (pt) 2007-11-20
AU2005244128A1 (en) 2005-11-24
AU2005244128B2 (en) 2009-06-25

Similar Documents

Publication Publication Date Title
US20240398923A1 (en) Subunit vaccine delivery platform for robust humoral and cellular immune responses
Wang et al. Gold nanoparticles conjugating recombinant influenza hemagglutinin trimers and flagellin enhanced mucosal cellular immunity
Ghaffarifar Plasmid DNA vaccines: where are we now
Sivakumar et al. Vaccine adjuvants–current status and prospects on controlled release adjuvancity
Stano et al. Nanoparticle size influences the magnitude and quality of mucosal immune responses after intranasal immunization
Lee et al. Recent advances of vaccine adjuvants for infectious diseases
EP2042193A1 (en) RNA Vaccines
JP2007530430A (ja) パターン認識受容体−リガンド：脂質複合体を使用するワクチン
WO2006097530A3 (en) Cat allergen fusion proteins and uses thereof
Zhang et al. PH-controlled release of antigens using mesoporous silica nanoparticles delivery system for developing a fish oral vaccine
WO2003051394A3 (en) Calcium phosphate particles as mucosal adjuvants
US20210100880A1 (en) System and method for microneedle delivery of microencapsulated vaccine and bioactive proteins
Hashemzadeh et al. Vaccines based on virus-like nano-particles for use against Middle East Respiratory Syndrome (MERS) coronavirus
WO2003090687A8 (en) Using heat shock proteins to increase immune response
MXPA06012838A (es) Vacuna de malaria pulmonar.
Tafaghodi et al. Immunization against leishmaniasis by PLGA nanospheres loaded with an experimental autoclaved Leishmania major (ALM) and Quillaja saponins.
EP2899203A3 (en) Leishmania vaccine using sand fly salivary immunogen
WO2005012538A3 (en) Accelerated vaccination
Tafaghodi et al. Immunization against cutaneous leishmaniasis by alginate microspheres loaded with autoclaved Leishmania Major (ALM) and Quillaja saponins
MuZikova et al. Macromolecular systems for vaccine delivery
CA2366056A1 (en) Non-spreading pestivirus
Goyal et al. Advancement in polymer-based carrier for DNA vaccine
Gandhapudi et al. Recombinant Protein Vaccines Formulated with Enantio-Specific Cationic Lipid R-DOTAP Induce Protective Cellular and Antibody-Mediated Immune Responses in Mice. Viruses. 2023; 15 (2): 432
CN104189922B (zh) 一种载新城疫DNA疫苗Ag@SiO2纳米粒的制备方法
Liu et al. Silica-calcium phosphate nanoparticles delivering recombinant influenza hemagglutinin DNA can induce long-lasting T cell immune cross-protection in mice

Legal Events

Date Code Title Description
FA Abandonment or withdrawal